logo-loader
viewActinogen Medical Ltd

Actinogen Limited readies to reveal clinical data

au_books350_56089951eb91f.jpg

Actinogen Limited (ASX:ACW) has been granted a trading halt by the ASX pending the results of the CSF clinical data.

The company is focussed on the treatment of Alzheimer’s disease and mild cognitive impairment.

The halt will remain in place until the opening of trade on Wednesday 30th September 2015, or earlier if an announcement is made to the market.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: Actinogen Medical Ltd

Price: 0.0235 AUD

ASX:ACW
Market: ASX
Market Cap: $26.23 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Time to take out some insurance against US stock markets says Alto Capital's...

Tony Locantro, from Alto Capital, says he is telling his clients to take out some insurance against the value of the Dow Jones and S&P too, which he believes are at ‘stupid’ levels. Clients are making massive returns, he says, I am recommending they buy short-side ETFs with the plan to...

1 hour, 4 minutes ago

2 min read